Acute Leukemia

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting 2024 that examined the use of menin inhibitors in patients with leukemia.

The FDA approved revumenib for the treatment of certain patients with advanced acute leukemia.

Use of post-transplant cyclophosphamide prophylaxis to prevent graft-versus-host disease could greatly expand access to hematopoietic stem cell transplantation, according to results of a retrospective study.

Use of blinatumomab with consolidation chemotherapy significantly extended OS for adults with minimal residual disease-negative B-cell precursor acute lymphoblastic leukemia, according to randomized phase 3 study results.

Women who undergo allogeneic hematopoietic cell transplantation can get pregnant and have healthy children, according to results of a retrospective study conducted in Germany.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

Healio spoke with Nikki Yuill, LCSW, and Michelle Rajotte, LMSW, the director and associate director of The Leukemia & Lymphoma Society’s Information Resource Center, about the importance of supportive care in young adults with leukemia.

Revumenib conferred complete remission or complete remission with partial hematologic recovery in nearly one-quarter of patients with two acute leukemia subtypes, according to the agent’s manufacturer.

Two teenagers with T-cell acute lymphoblastic leukemia achieved complete molecular remission after receiving a donor-based investigational chimeric antigen receptor T-cell therapy, phase 1 study results showed.